AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer
Phase 3
Completed
- Conditions
- Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN
- Interventions
- First Posted Date
- 2015-02-24
- Last Posted Date
- 2021-02-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 736
- Registration Number
- NCT02369874
- Locations
- 🇺🇦
Research Site, Zaporizhzhia, Ukraine
T790M Mutation Positive 2nd Line STandard of cAre Registry
Withdrawn
- Conditions
- Non Small Cell Lung Cancer
- First Posted Date
- 2015-02-23
- Last Posted Date
- 2015-07-08
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT02368990
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)
- First Posted Date
- 2015-02-20
- Last Posted Date
- 2016-06-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT02367066
- Locations
- 🇺🇸
Research Site, Chula Vista, California, United States
Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions
Phase 1
Completed
- Conditions
- PharmacokineticsAUCRelative BioavailabilityCmax
- Interventions
- Drug: D1400147Drug: D14000136Drug: D14000137Drug: Epanova®
- First Posted Date
- 2015-02-09
- Last Posted Date
- 2017-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 137
- Registration Number
- NCT02359045
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
Non-inteRvEntional Study to Observe rAtionaLe to Select add-on TherapY for Type 2 Diabetes Inadequately Controlled With Metformin.
Completed
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2015-02-04
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1005
- Registration Number
- NCT02355145
- Locations
- 🇧🇬
Research Site, Stara Zagora, Bulgaria
A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.
Phase 2
Completed
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLDHypertriglyceridemia
- Interventions
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 78
- Registration Number
- NCT02354976
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
Phase 3
Completed
- Conditions
- Non - Small Cell Lung Cancer NSCLC
- Interventions
- Drug: MEDI4736 (durvalumab)Drug: MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4)
- First Posted Date
- 2015-02-02
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 597
- Registration Number
- NCT02352948
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
Autoinjector Device Assessment Study
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: Syringe with exenatide suspensionDrug: Auto-injector with exenatide suspension
- First Posted Date
- 2015-01-29
- Last Posted Date
- 2015-02-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3052
- Registration Number
- NCT02349802
- Locations
- 🇺🇸
Research Site, Lincoln, Nebraska, United States
Observational Multicenter Non-interventional Study on COPD Patients Treatment Strategies at the Time of Hospital Discharge and Within 12 Months of Follow-up on an Outpatient Primary Care Basement
Completed
- Conditions
- COPD
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2017-12-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1250
- Registration Number
- NCT02346292
- Locations
- 🇷🇺
Research Site, Yaroslavl, Russian Federation
Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours
Phase 1
Completed
- Conditions
- Advanced Solid Tumours
- Interventions
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2019-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 19
- Registration Number
- NCT02341456
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of